Menu Search
Equities

Clinical Laserthermia Systems AB

CLS B:STO

Clinical Laserthermia Systems AB

Actions
  • Price (SEK)4.50
  • Today's Change0.72 / 19.05%
  • Shares traded68.13k
  • 1 Year change-82.57%
  • Beta0.6612
Data delayed at least 15 minutes, as of Nov 22 2024 17:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in SEKIncome statement in SEKView more

Year on year Clinical Laserthermia Systems AB had net income fall 12.92% from a loss of 70.66m to a larger loss of 79.79m despite a 31.99% increase in revenues from 6.27m to 8.27m. An increase in the selling, general and administrative costs as a percentage of sales from 254.64% to 281.88% was a component in the falling net income despite rising revenues.
Gross margin-175.42%
Net profit margin-347.76%
Operating margin-321.88%
Return on assets-92.16%
Return on equity-102.60%
Return on investment-103.14%
More ▼

Cash flow in SEKView more

In 2023, Clinical Laserthermia Systems AB increased its cash reserves by 44.78%, or 4.74m. Cash Flow from Financing totalled 76.69m or 927.04% of revenues. In addition the company used 66.46m for operations while cash used for investing totalled 5.50m.
Cash flow per share-6.86
Price/Cash flow per share--
Book value per share4.39
Tangible book value per share2.96
More ▼

Balance sheet in SEKView more

Clinical Laserthermia Systems AB has a strong Balance Sheet and has consistently grown its cash reserves over the last four years to total 15.33m.
Current ratio3.11
Quick ratio2.39
Total debt/total equity0.0074
Total debt/total capital0.0077
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.